Assessing interindividual variability by Bayesian-PBPK modeling

The description of interindividual variability and the ADME-related sources of such variability (ADME: absorption, distribution, metabolization, excretion) is an essential element in clinical drug development to identify potentially relevant subgroups of non-responders or high-risk patients. The use of physiologically-based pharmacokinetic (PBPK) models supports a mechanistic understanding of the underlying ADME processes related to drug pharmacokinetics. In addition, the integration of Bayesian statistics into PBPK applications has allowed thorough assessment of interindividual variability and uncertainty of the pharmacokinetic behavior of drugs and underlying model parameters. Recent applications of Bayesian-PBPK approaches include subgroup stratification or improvement of the robustness of pharmacokinetic extrapolations.

[1]  F. Theil,et al.  Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. , 2001, Journal of pharmaceutical sciences.

[2]  Stefan Willmann,et al.  Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification , 2013, In Silico Pharmacology.

[3]  A. Gelman,et al.  Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .

[4]  J. Hampe,et al.  A Mechanistic, Model-Based Approach to Safety Assessment in Clinical Development , 2012, CPT: pharmacometrics & systems pharmacology.

[6]  Ivan Nestorov,et al.  Whole-body physiologically based pharmacokinetic models , 2007, Expert opinion on drug metabolism & toxicology.

[7]  Leon Aarons,et al.  Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data , 2015, British journal of clinical pharmacology.

[8]  Markus Krauss,et al.  Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations , 2015, PloS one.

[9]  Leon Aarons,et al.  Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach , 2014, Pharmaceutical Research.

[10]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[11]  T. Leil,et al.  A Bayesian Perspective on Estimation of Variability and Uncertainty in Mechanism-Based Models , 2014, CPT: pharmacometrics & systems pharmacology.

[12]  Marie Davidian,et al.  Nonlinear models for repeated measurement data: An overview and update , 2003 .

[13]  J. Lippert,et al.  Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban , 2013, Clinical Pharmacokinetics.

[14]  F. LaCreta,et al.  Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism–Based Pharmacometric Model , 2014, CPT: pharmacometrics & systems pharmacology.

[15]  Ivelina Gueorguieva,et al.  Diazepam Pharamacokinetics from Preclinical to Phase I Using a Bayesian Population Physiologically Based Pharmacokinetic Model with Informative Prior Distributions in Winbugs , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[16]  Kennon Heard,et al.  A novel approach for estimating ingested dose associated with paracetamol overdose. , 2016, British journal of clinical pharmacology.

[17]  N. Vermeulen,et al.  Molecular aspects of paracetamol-induced hepatotoxicity and its mechanism-based prevention. , 1992, Drug metabolism reviews.

[18]  Brad Reisfeld,et al.  Characterizing the Effects of Race/Ethnicity on Acetaminophen Pharmacokinetics Using Physiologically Based Pharmacokinetic Modeling , 2016, European Journal of Drug Metabolism and Pharmacokinetics.

[19]  N Parrott,et al.  Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective , 2015, Clinical pharmacology and therapeutics.

[20]  L Kuepfer,et al.  Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model , 2016, CPT: pharmacometrics & systems pharmacology.

[21]  Stefan Willmann,et al.  Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition. , 2012, Molecular diagnosis & therapy.

[22]  T. Eissing,et al.  Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals , 2016, Clinical Pharmacokinetics.

[23]  L Kuepfer,et al.  Clinical Translation in the Virtual Liver Network , 2014, CPT: pharmacometrics & systems pharmacology.

[24]  U. Hofmann,et al.  A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation. , 2015, Journal of pharmaceutical sciences.

[25]  F Y Bois,et al.  Statistical issues in toxicokinetic modeling: a bayesian perspective. , 2000, Environmental health perspectives.

[26]  Masoud Jamei,et al.  Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance , 2016, Current Pharmacology Reports.

[27]  Stefan Willmann,et al.  Pharmacogenomics of Codeine, Morphine, and Morphine-6-Glucuronide , 2012, Molecular Diagnosis & Therapy.

[28]  M. Jamei,et al.  PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. , 2010, Toxicology.

[29]  Lars Kuepfer,et al.  Multiscale mechanistic modeling in pharmaceutical research and development. , 2012, Advances in experimental medicine and biology.

[30]  Weihsueh A. Chiu,et al.  Addressing Human Variability in Next-Generation Human Health Risk Assessments of Environmental Chemicals , 2012, Environmental health perspectives.

[31]  K. Venkatakrishnan,et al.  Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities , 2015, Clinical pharmacology and therapeutics.

[32]  Brad Reisfeld,et al.  Physiologically based modeling of the pharmacokinetics of acetaminophen and its major metabolites in humans using a Bayesian population approach , 2015, European Journal of Drug Metabolism and Pharmacokinetics.

[33]  Fabian J Theis,et al.  High-dimensional Bayesian parameter estimation: case study for a model of JAK2/STAT5 signaling. , 2013, Mathematical biosciences.

[34]  R. Iyengar,et al.  Merging Systems Biology with Pharmacodynamics , 2012, Science Translational Medicine.

[35]  Eric D Kolaczyk,et al.  Perturbation Detection Through Modeling of Gene Expression on a Latent Biological Pathway Network: A Bayesian Hierarchical Approach , 2014, Journal of the American Statistical Association.

[36]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[37]  Weihsueh A Chiu,et al.  Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach. , 2009, Toxicology and applied pharmacology.

[38]  Andrew Gelman,et al.  Handbook of Markov Chain Monte Carlo , 2011 .

[39]  Mitchell R. McGill,et al.  Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity , 2012, Drug metabolism reviews.

[40]  P. Neuvonen,et al.  SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin , 2006, Clinical pharmacology and therapeutics.